Rabia Asim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Rabia Asim has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Bazil Azeem
Department of Medicine, Shaheed Mohtarma Benazir Bhutto Medical College Lyari, Karachi, Pakistan
5 shared publications - Mata-E-Alla Dogar
Department of Medicine, Shaheed Mohtarma Benazir Bhutto Medical College Lyari, Karachi, Pakistan
4 shared publications - Muhammad Abdullah Naveed
Department of Cardiology, Dow Medical College Dow University of Health Sciences Karachi Pakistan
2 shared publications - Syeda Verisha Batool
Dow University of Health Sciences, Pakistan
2 shared publications - Amisha Kumari
Dow University of Health Sciences, Karachi, Pakistan
1 shared publication - Anus Aijaz Ahmed Khan
Dow University of Health Sciences, Karachi, Pakistan
1 shared publication
Latest Publications
- 2 May 2026
- Published by Springer Nature in American Journal of Cardiovascular Drugs
- Vol. 26 (4) , 453-465
Formulation-Specific Cardiovascular Outcomes with High-Dose Eicosapentaenoic Acid: A Systematic Review and Meta-analysis
Background/Objective Residual cardiovascular risk persists despite intensive statin therapy in patients with established atherosclerotic cardiovascular disease (CVD). Omega-3 fatty acids, particularly high-dose eicosapentaenoic acid (EPA), have been proposed as adjunctive therapy, yet trial results conflict, likely due to formulation differences. We conducted a formulation-focused meta-analysis to determine whether high-dose EPA-dominant supplementation reduces cardiovascular events and to quantify the impact of mixed EPA/docosahexaenoic acid (DHA) regimens on efficacy. Methods Following Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2020 guidelines, we searched MEDLINE, Embase, CENTRAL, and trial registries through May 2025 for randomized controlled trials, including placebo-controlled and open-label designs, of high-dose EPA-dominant omega-3 (≥ 1.8 g/day; ≥ 50% EPA) in adults with established CVD or other high-risk settings. Six trials (n = 42,738; 31–85% male) were eligible. Random-effects models generated pooled risk ratios (RRs), with I2 assessing heterogeneity; sensitivity analyses excluded mixed EPA/DHA formulations. Imaging surrogate outcomes were summarized narratively when study modalities were not directly comparable. Results EPA-based therapy significantly reduced hospitalizations for unstable angina (RR 0.75, 95% CI 0.66–0.87; I2 = 0%). Overall effects on recurrent myocardial infarction and revascularization were not statistically significant, but both became significant after exclusion of STRENGTH, the only mixed EPA/DHA cardiovascular outcomes trial. No significant effect was observed for ischemic stroke, cardiovascular death, or high-sensitivity C-reactive protein (hs-CRP). CHERRY and EVAPORATE both suggested attenuation of plaque progression, but these imaging studies were not pooled because intravascular ultrasound and coronary computed tomography angiography-derived measures were not directly comparable. Conclusion High-dose EPA-dominant therapy was associated with fewer unstable angina hospitalizations, and formulation appeared to modify clinical benefit. Among blinded, placebo-controlled, cardiovascular outcomes trials, 4 g/day icosapent ethyl is the only formulation independently associated with reduced cardiovascular events. Larger formulation-specific trials are needed to clarify the roles of purified EPA, mixed EPA/DHA regimens, and patient selection. Registration PROSPERO identifier number: CRD420251063069.
- 2 May 2026
- Published by Springer Nature in American Journal of Cardiovascular Drugs
- Vol. 26 (4) , 453-465
Formulation-Specific Cardiovascular Outcomes with High-Dose Eicosapentaenoic Acid: A Systematic Review and Meta-analysis
Background/Objective Residual cardiovascular risk persists despite intensive statin therapy in patients with established atherosclerotic cardiovascular disease (CVD). Omega-3 fatty acids, particularly high-dose eicosapentaenoic acid (EPA), have been proposed as adjunctive therapy, yet trial results conflict, likely due to formulation differences. We conducted a formulation-focused meta-analysis to determine whether high-dose EPA-dominant supplementation reduces cardiovascular events and to quantify the impact of mixed EPA/docosahexaenoic acid (DHA) regimens on efficacy. Methods Following Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2020 guidelines, we searched MEDLINE, Embase, CENTRAL, and trial registries through May 2025 for randomized controlled trials, including placebo-controlled and open-label designs, of high-dose EPA-dominant omega-3 (≥ 1.8 g/day; ≥ 50% EPA) in adults with established CVD or other high-risk settings. Six trials (n = 42,738; 31–85% male) were eligible. Random-effects models generated pooled risk ratios (RRs), with I2 assessing heterogeneity; sensitivity analyses excluded mixed EPA/DHA formulations. Imaging surrogate outcomes were summarized narratively when study modalities were not directly comparable. Results EPA-based therapy significantly reduced hospitalizations for unstable angina (RR 0.75, 95% CI 0.66–0.87; I2 = 0%). Overall effects on recurrent myocardial infarction and revascularization were not statistically significant, but both became significant after exclusion of STRENGTH, the only mixed EPA/DHA cardiovascular outcomes trial. No significant effect was observed for ischemic stroke, cardiovascular death, or high-sensitivity C-reactive protein (hs-CRP). CHERRY and EVAPORATE both suggested attenuation of plaque progression, but these imaging studies were not pooled because intravascular ultrasound and coronary computed tomography angiography-derived measures were not directly comparable. Conclusion High-dose EPA-dominant therapy was associated with fewer unstable angina hospitalizations, and formulation appeared to modify clinical benefit. Among blinded, placebo-controlled, cardiovascular outcomes trials, 4 g/day icosapent ethyl is the only formulation independently associated with reduced cardiovascular events. Larger formulation-specific trials are needed to clarify the roles of purified EPA, mixed EPA/DHA regimens, and patient selection. Registration PROSPERO identifier number: CRD420251063069.
- 24 March 2026
- Published by Innovacore Center for Research & Biotech in INNOVAPATH
- Vol. 2 (1) , 15
Concizumab: A Subcutaneous Innovation in Hemophilia A and B—Targeting Factor VIII/IX Deficiency and Inhibitor Management
Introduction: Hemophilia is a rare X-linked bleeding disorder caused by deficiencies in clotting factors VIII (Hemophilia A) or IX (Hemophilia B), leading to spontaneous joint bleeding and recurrent bleeding after trauma. The treatment of hemophilia includes IV factor replacement therapy. It is limited by high cost, inhibitor development, short half-life, and significant psychological and financial burden. Concizumab, offers a convenient subcutaneous alternative that enhances thrombin generation and improves clot formation. Objective: To evaluate the efficacy and safety of concizumab in hemophilia A and B (with or without inhibitors) and to compare its performance with current therapeutic options in the modern treatment landscape. Result: Concizumab is a monoclonal antibody that blocks the K2 domain of TFPI, preventing FXa inhibition and thereby restoring thrombin generation to improve coagulation in patients with hemophilia. Before concizumab, treatments like emicizumab, gene therapy, and fitusiran helped reduce bleeding but each had issues such as high cost, safety risks, or limited use. Because of these problems, there was still a need for a safer and more reliable option that works for all types of hemophilia, something concizumab now provides. Concizumab showed strong bleeding reduction and good Subcutaneous bioavailability in preclinical work. Phase 1 trials supported its safety. Explorer 3 confirmed that higher doses lower TFPI and increase thrombin. Additionally, explorer 7 and 8 showed dramatic ABR declines, zero median ABR in inhibitor patients and 79-86% reductions in non-inhibitors, with no new thromboses after dose changes. However, its use is limited by high cost, competition with existing therapies, administration challenges, and restricted availability; especially in low-income countries. Safety concerns and the need for monitoring also add barriers despite its proven effectiveness. Conclusion:Concizumab is primarily used for hemophilia prophylaxis but dueto TFPI blocking, could also shows potential in conditions like FVETBD, pancreatic cancer, atherosclerosis, and Alzheimer’s complications. Ongoing studies highlight its promise as a versatile non-factor therapy that may improve personalized care and quality of life.
- 24 March 2026
- Published by Innovacore Center for Research & Biotech in INNOVAPATH
- Vol. 2 (1) , 15
Concizumab: A Subcutaneous Innovation in Hemophilia A and B—Targeting Factor VIII/IX Deficiency and Inhibitor Management
Introduction: Hemophilia is a rare X-linked bleeding disorder caused by deficiencies in clotting factors VIII (Hemophilia A) or IX (Hemophilia B), leading to spontaneous joint bleeding and recurrent bleeding after trauma. The treatment of hemophilia includes IV factor replacement therapy. It is limited by high cost, inhibitor development, short half-life, and significant psychological and financial burden. Concizumab, offers a convenient subcutaneous alternative that enhances thrombin generation and improves clot formation. Objective: To evaluate the efficacy and safety of concizumab in hemophilia A and B (with or without inhibitors) and to compare its performance with current therapeutic options in the modern treatment landscape. Result: Concizumab is a monoclonal antibody that blocks the K2 domain of TFPI, preventing FXa inhibition and thereby restoring thrombin generation to improve coagulation in patients with hemophilia. Before concizumab, treatments like emicizumab, gene therapy, and fitusiran helped reduce bleeding but each had issues such as high cost, safety risks, or limited use. Because of these problems, there was still a need for a safer and more reliable option that works for all types of hemophilia, something concizumab now provides. Concizumab showed strong bleeding reduction and good Subcutaneous bioavailability in preclinical work. Phase 1 trials supported its safety. Explorer 3 confirmed that higher doses lower TFPI and increase thrombin. Additionally, explorer 7 and 8 showed dramatic ABR declines, zero median ABR in inhibitor patients and 79-86% reductions in non-inhibitors, with no new thromboses after dose changes. However, its use is limited by high cost, competition with existing therapies, administration challenges, and restricted availability; especially in low-income countries. Safety concerns and the need for monitoring also add barriers despite its proven effectiveness. Conclusion:Concizumab is primarily used for hemophilia prophylaxis but dueto TFPI blocking, could also shows potential in conditions like FVETBD, pancreatic cancer, atherosclerosis, and Alzheimer’s complications. Ongoing studies highlight its promise as a versatile non-factor therapy that may improve personalized care and quality of life.
- Open Access
- 28 January 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (3) , 2325-2334
Neurocognitive outcomes in children with craniosynostosis after surgical correction: a narrative review
Importance: Craniosynostosis, the premature fusion of cranial sutures, carries significant clinical implications beyond skull morphology. Its restriction of brain growth and potential for raised intracranial pressure pose notable risks for long-term neurocognitive development. Both syndromic and nonsyndromic forms have been increasingly associated with deficits in cognition, behavior, and academic performance, underlining the need for careful neurodevelopmental monitoring even after surgical intervention. Observations: Current literature demonstrates heterogeneous neurocognitive outcomes post-surgery. While early surgical correction, particularly before 6 months of age, is associated with improved cognitive trajectories, especially in sagittal synostosis, results remain inconsistent across craniosynostosis subtypes and surgical approaches. Syndromic cases generally fare worse than nonsyndromic ones, regardless of surgical timing. Notably, emerging evidence reveals that even children with single-suture, nonsyndromic craniosynostosis may experience subtle yet meaningful impairments in executive function, language, and attention. Variability in surgical technique, assessment tools, and follow-up duration complicates the interpretation of outcomes. Conclusions and Relevance: Although surgical correction remains the cornerstone of management, it does not uniformly normalize neurocognitive development. The findings underscore the necessity of a multidisciplinary, longitudinal approach to care – integrating neurosurgical, neuropsychological, and rehabilitative strategies. Future research must prioritize standardized cognitive assessments, extended follow-up into adolescence, and controlled comparisons across surgical methods. Understanding genetic, environmental, and procedural moderators of outcome is essential to optimizing long-term quality of life for affected children.
- 28 January 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (3) , 2325-2334
Open AccessNeurocognitive outcomes in children with craniosynostosis after surgical correction: a narrative review
Importance: Craniosynostosis, the premature fusion of cranial sutures, carries significant clinical implications beyond skull morphology. Its restriction of brain growth and potential for raised intracranial pressure pose notable risks for long-term neurocognitive development. Both syndromic and nonsyndromic forms have been increasingly associated with deficits in cognition, behavior, and academic performance, underlining the need for careful neurodevelopmental monitoring even after surgical intervention. Observations: Current literature demonstrates heterogeneous neurocognitive outcomes post-surgery. While early surgical correction, particularly before 6 months of age, is associated with improved cognitive trajectories, especially in sagittal synostosis, results remain inconsistent across craniosynostosis subtypes and surgical approaches. Syndromic cases generally fare worse than nonsyndromic ones, regardless of surgical timing. Notably, emerging evidence reveals that even children with single-suture, nonsyndromic craniosynostosis may experience subtle yet meaningful impairments in executive function, language, and attention. Variability in surgical technique, assessment tools, and follow-up duration complicates the interpretation of outcomes. Conclusions and Relevance: Although surgical correction remains the cornerstone of management, it does not uniformly normalize neurocognitive development. The findings underscore the necessity of a multidisciplinary, longitudinal approach to care – integrating neurosurgical, neuropsychological, and rehabilitative strategies. Future research must prioritize standardized cognitive assessments, extended follow-up into adolescence, and controlled comparisons across surgical methods. Understanding genetic, environmental, and procedural moderators of outcome is essential to optimizing long-term quality of life for affected children.
- Open Access
- 26 November 2025
- Published by Wiley in Clinical Cardiology
- Vol. 48 (12) , e70211
Dual‐Targeted Therapy in Cardiometabolic Risk: A Meta‐Analysis of Telmisartan‐Based Combinations for Hypertension and Dyslipidemia
Background: Hypertension often coexists with dyslipidemia, requiring combination therapy. Telmisartan, combined with amlodipine or rosuvastatin, targets these conditions. This meta‐analysis evaluates the efficacy and safety of these combinations in adults with hypertension and dyslipidemia. Methods: A systematic search was conducted in Cochrane Central, MEDLINE/PubMed, ClinicalTrials.gov, and ScienceDirect (as of June 2024) for randomized controlled trials (RCTs) comparing telmisartan plus amlodipine versus telmisartan plus rosuvastatin in adults (≥ 18 years) with hypertension and dyslipidemia. A random‐effects model was used with RevMan 5.4.1. The risk of bias and heterogeneity were assessed with the Cochrane Risk of Bias Tool and the I ² statistic. Results: Three RCTs involving 320 participants were included. At 4 weeks, telmisartan + amlodipine yielded greater sSBP (sitting Systolic Blood Pressure) reduction compared to telmisartan + rosuvastatin (MD = −10.93 mmHg; 95% CI: −19.02 to −2.83; p = 0.008; I ² = 70%). sDBP (sitting Diastolic Blood Pressure) reductions were greater in the amlodipine group at 8 weeks (MD = −8.59 mmHg; 95% CI: −13.35 to −3.82; p = 0.0004; I ² = 58%). Conversely, LDL‐C reduction was favored by telmisartan + rosuvastatin, with significant effects observed at both 4 weeks (MD = 85.98 mg/dL) and 8 weeks (MD = 79.75 mg/dL). TEAE incidence did not differ significantly (RR = 1.23; 95% CI: 0.75–2.04; p = 0.41; I ² = 0%). Conclusion: Telmisartan + amlodipine demonstrates superior antihypertensive efficacy, while telmisartan + rosuvastatin more effectively lowers LDL‐C. Safety profiles are comparable. Findings support the selection of a regimen based on individualized therapeutic goals.
- 26 November 2025
- Published by Wiley in Clinical Cardiology
- Vol. 48 (12) , e70211
Open AccessDual‐Targeted Therapy in Cardiometabolic Risk: A Meta‐Analysis of Telmisartan‐Based Combinations for Hypertension and Dyslipidemia
Background: Hypertension often coexists with dyslipidemia, requiring combination therapy. Telmisartan, combined with amlodipine or rosuvastatin, targets these conditions. This meta‐analysis evaluates the efficacy and safety of these combinations in adults with hypertension and dyslipidemia. Methods: A systematic search was conducted in Cochrane Central, MEDLINE/PubMed, ClinicalTrials.gov, and ScienceDirect (as of June 2024) for randomized controlled trials (RCTs) comparing telmisartan plus amlodipine versus telmisartan plus rosuvastatin in adults (≥ 18 years) with hypertension and dyslipidemia. A random‐effects model was used with RevMan 5.4.1. The risk of bias and heterogeneity were assessed with the Cochrane Risk of Bias Tool and the I ² statistic. Results: Three RCTs involving 320 participants were included. At 4 weeks, telmisartan + amlodipine yielded greater sSBP (sitting Systolic Blood Pressure) reduction compared to telmisartan + rosuvastatin (MD = −10.93 mmHg; 95% CI: −19.02 to −2.83; p = 0.008; I ² = 70%). sDBP (sitting Diastolic Blood Pressure) reductions were greater in the amlodipine group at 8 weeks (MD = −8.59 mmHg; 95% CI: −13.35 to −3.82; p = 0.0004; I ² = 58%). Conversely, LDL‐C reduction was favored by telmisartan + rosuvastatin, with significant effects observed at both 4 weeks (MD = 85.98 mg/dL) and 8 weeks (MD = 79.75 mg/dL). TEAE incidence did not differ significantly (RR = 1.23; 95% CI: 0.75–2.04; p = 0.41; I ² = 0%). Conclusion: Telmisartan + amlodipine demonstrates superior antihypertensive efficacy, while telmisartan + rosuvastatin more effectively lowers LDL‐C. Safety profiles are comparable. Findings support the selection of a regimen based on individualized therapeutic goals.
- Open Access
- 23 October 2025
- Published by Wolters Kluwer Health in Journal of Glaucoma
- Vol. 35 (4) , 261-266
Micropulse Cyclophotocoagulation Versus Continuous Wave Cyclophotocoagulation: A Meta-Analysis
Précis: In this systematic review, we find that CW-CPC produces more sustained IOP lowering in children compared with MP-CPC. Purpose: Micropulse cyclophotocoagulation (MP-CPC) and continuous cyclophotocoagulation (CW-CPC) are both surgical interventions used to decrease intraocular pressure (IOP) in pediatric glaucoma. Recent publications have shown conflicting results regarding the effectiveness of MP-CPC compared with CW-CPC, which this systematic review and meta-analysis aims to evaluate. Methods: From inception through March 2025, PubMed, Embase, Scopus, Cochrane Library, and ScienceDirect were searched for studies comparing MP-CPC and CW-CPC in treating pediatric glaucoma, with IOP reported at different time intervals. A random effects model was used across all analyses. Results: At 12 months, CW-CPC showed a significantly greater reduction in IOP compared with MP-CPC (MD: −6.88 mm Hg, 95% CI: −9.46 to −4.30; P < 0.00001). No significant differences in IOP lowering were observed at 1, 3, and 6 months. Overall, CW-CPC was superior in reducing IOP (MD: −4.23 mm Hg, 95% CI: −6.51 to −1.95; P = 0.0003; I² = 80%) at the last follow-up. Conclusion: CW-CPC shows a significantly greater reduction in IOP than MP-CPC, particularly at long-term follow-up. These findings highlight the sustained efficacy of CW-CPC compared with MP-CPC in the management of pediatric glaucoma.
- 23 October 2025
- Published by Wolters Kluwer Health in Journal of Glaucoma
- Vol. 35 (4) , 261-266
Open AccessMicropulse Cyclophotocoagulation Versus Continuous Wave Cyclophotocoagulation: A Meta-Analysis
Précis: In this systematic review, we find that CW-CPC produces more sustained IOP lowering in children compared with MP-CPC. Purpose: Micropulse cyclophotocoagulation (MP-CPC) and continuous cyclophotocoagulation (CW-CPC) are both surgical interventions used to decrease intraocular pressure (IOP) in pediatric glaucoma. Recent publications have shown conflicting results regarding the effectiveness of MP-CPC compared with CW-CPC, which this systematic review and meta-analysis aims to evaluate. Methods: From inception through March 2025, PubMed, Embase, Scopus, Cochrane Library, and ScienceDirect were searched for studies comparing MP-CPC and CW-CPC in treating pediatric glaucoma, with IOP reported at different time intervals. A random effects model was used across all analyses. Results: At 12 months, CW-CPC showed a significantly greater reduction in IOP compared with MP-CPC (MD: −6.88 mm Hg, 95% CI: −9.46 to −4.30; P < 0.00001). No significant differences in IOP lowering were observed at 1, 3, and 6 months. Overall, CW-CPC was superior in reducing IOP (MD: −4.23 mm Hg, 95% CI: −6.51 to −1.95; P = 0.0003; I² = 80%) at the last follow-up. Conclusion: CW-CPC shows a significantly greater reduction in IOP than MP-CPC, particularly at long-term follow-up. These findings highlight the sustained efficacy of CW-CPC compared with MP-CPC in the management of pediatric glaucoma.
- 9 September 2025
- Published by Elsevier in Clinics and Research in Hepatology and Gastroenterology
- Vol. 49 (8) , 102684
Hepatitis B and C in Pakistan: A silent crisis demanding urgent action
- 9 September 2025
- Published by Elsevier in Clinics and Research in Hepatology and Gastroenterology
- Vol. 49 (8) , 102684
Hepatitis B and C in Pakistan: A silent crisis demanding urgent action
- 5 December 2024
- Published by Springer Nature in AI and Ethics
- Vol. 5 (3) , 2015-2020
Multi-faceted role of artificial intelligence (AI) in cardiopulmonary resuscitation (CPR): a narrative review
- 5 December 2024
- Published by Springer Nature in AI and Ethics
- Vol. 5 (3) , 2015-2020
Multi-faceted role of artificial intelligence (AI) in cardiopulmonary resuscitation (CPR): a narrative review
- 9 October 2024
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 246, 108591
Letter to the editor “Cytokines in cerebrospinal fluid as a prognostic predictor after treatment of nusinersen in SMA patients” by Xi Cheng et al.
- 9 October 2024
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 246, 108591
Letter to the editor “Cytokines in cerebrospinal fluid as a prognostic predictor after treatment of nusinersen in SMA patients” by Xi Cheng et al.
- 9 October 2024
- Published by Springer Nature in Neurosurgical Review
- Vol. 47 (1) , 1-2
Letter to the editor: “Radiographic characterization of OPLL progression in patients receiving laminoplasty with a minimum of two-years follow-up”
- 9 October 2024
- Published by Springer Nature in Neurosurgical Review
- Vol. 47 (1) , 1-2
Letter to the editor: “Radiographic characterization of OPLL progression in patients receiving laminoplasty with a minimum of two-years follow-up”
- 30 August 2024
- Published by Springer Nature in Neurosurgical Review
- Vol. 47 (1) , 1-2
Comment on “Non-fungible token integration in neurosurgery: a technical review”
- 30 August 2024
- Published by Springer Nature in Neurosurgical Review
- Vol. 47 (1) , 1-2
Comment on “Non-fungible token integration in neurosurgery: a technical review”